Similar articles

• Clinical use of monoclonal antibodies to the epidermal growth factor receptor in colorectal cancer.

  Burtness B. Burtness B. Oncology (Williston Park). 2007 Jul;21(8):964-70; discussion 970, 974, 976-7. Oncology (Williston Park). 2007. PMID: 17715697 Review.
• The use of EGFR inhibitors in colorectal cancer: is it clinically efficacious and cost-effective?

  Lien K, Berry S, Ko YJ, Chan KK. Lien K, et al. Expert Rev Pharmacoecon Outcomes Res. 2015 Feb;15(1):81-100. doi: 10.1586/14737167.2015.982100. Epub 2014 Nov 17. Expert Rev Pharmacoecon Outcomes Res. 2015. PMID: 25400031 Review.
• Epidermal growth factor receptor monoclonal antibodies for the treatment of metastatic colorectal cancer.

  Jean GW, Shah SR. Jean GW, et al. Pharmacotherapy. 2008 Jun;28(6):742-54. doi: 10.1592/phco.28.6.742. Pharmacotherapy. 2008. PMID: 18503402 Review.
• Anti-EGFR monoclonal antibodies for treatment of colorectal cancers: development of cetuximab and panitumumab.

  You B, Chen EX. You B, et al. J Clin Pharmacol. 2012 Feb;52(2):128-55. doi: 10.1177/0091270010395940. J Clin Pharmacol. 2012. PMID: 21427284 Review.
• Treatment with panitumumab after a severe infusion reaction to cetuximab in a patient with metastatic colorectal cancer: a case report.

  Heun J, Holen K. Heun J, et al. Clin Colorectal Cancer. 2007 May;6(7):529-31. doi: 10.3816/CCC.2007.n.019. Clin Colorectal Cancer. 2007. PMID: 17553202